Summit Therapeutics
SMMT
41 hedge funds and large institutions have $54.6M invested in Summit Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 6 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
27% more capital invested
Capital invested by funds: $42.9M → $54.6M (+$11.7M)
11% more funds holding
Funds holding: 37 → 41 (+4)
0.12% more ownership
Funds ownership: 11.09% → 11.21% (+0.12%)
Top Buyers
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$2.31M |
| 2 |
Millennium Management
New York
|
+$2.13M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$683K |
| 4 |
Goldman Sachs
New York
|
+$334K |
| 5 |
LCS
Levin Capital Strategies
New York
|
+$216K |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$3.03M |
| 2 |
Renaissance Technologies
New York
|
-$1.19M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
-$596K |
| 4 |
Morgan Stanley
New York
|
-$251K |
| 5 |
BP
BBR Partners
New York
|
-$235K |
SMMT Hedge Fund Activity: Q1 2021 in Review
41 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q1 2021, worth a combined $54.6M — up 27% from $42.9M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new SMMT positions and 6 closed out — a net gain of 4 holders — while 17 added to existing stakes and 8 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $2.31M. The largest seller was JP Morgan Chase, cutting an estimated $3.03M.
- 41 institutional investors held Summit Therapeutics (SMMT) as of Q1 2021, up from 37 in Q4 2020.
- Funds reported $54.6M of Summit Therapeutics stock for Q1 2021, up 27% quarter-over-quarter.
- 10 funds opened new Summit Therapeutics positions in Q1 2021 and 6 closed out, a net change of +4 holders.
- The largest Summit Therapeutics buyer in Q1 2021 was Polar Capital Holdings, an estimated $2.31M added.
- The largest Summit Therapeutics seller in Q1 2021 was JP Morgan Chase, an estimated $3.03M sold.
Based on aggregated 13F filings for Q1 2021.